Comparative Financial Analysis of KROS and Janux Therapeutics
1 report, 1 independent
Updated Sun 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
KROS and Janux Therapeutics have been identified as small-cap healthcare companies. A comparison of the two companies showed that KROS has higher revenue and earnings per share than Janux Therapeutics. Janux Therapeutics is currently trading at a lower price-to-earnings ratio, while KROS has a lower stock price volatility.
From tickerreport.com
Why it matters
The comparison highlights differences in financial risk and valuation between the two firms. Janux Therapeutics has a beta of 2.4, indicating higher stock price volatility compared to KROS's beta of 1.12. Institutional ownership is strong for both, with Janux Therapeutics holding 75.4% of its shares.
From tickerreport.com